Defining the Phenotype of Complicated Delirium Associated with Long-Term Cognitive Decline
定义与长期认知衰退相关的复杂谵妄的表型
基本信息
- 批准号:10405120
- 负责人:
- 金额:$ 14.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-15 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAlzheimer’s disease biomarkerBiological MarkersBrainCerebrospinal FluidCessation of lifeClinicalClinical DataCohort StudiesDataData AnalysesDecision MakingDeliriumDementiaDevelopmentEarly identificationFamilyFamily PolicyFollow-Up StudiesFosteringFutureGoalsHealth Care CostsImpaired cognitionInflammationInterviewJudgmentLongterm Follow-upMeasuresMethodologyMethodsModelingModernizationNursing HomesOperative Surgical ProceduresOrthopedic SurgeryOutcomePatientsPerioperativePersonsPhenotypePolicy MakerPostoperative PeriodPrimary PreventionProcessReproducibilityResearch DesignRiskSamplingSecondary PreventionSerumSeveritiesSubgroupSyndromeTimeValidationWorkadverse outcomeclinical practicecognitive performancecohortcrosslinkimprovedinsightmild cognitive impairmentneuroimagingneurophysiologynovelpostoperative deliriumpredictive modelingpreventive interventionprognosticsecondary analysisservice utilizationtargeted treatment
项目摘要
ABSTRACT
Delirium has been considered a transient, reversible syndrome. However, long-term follow-up studies suggest
delirium is not always transient and reversible, and is correlated with increased risk of bad outcomes, such as
persistent and accelerated cognitive decline, Alzheimer's disease or dementia, death, and excess service utili-
zation. We have demonstrated that about half of people who develop postoperative delirium return to preoper-
ative baseline cognitive performance levels within about 8 weeks of surgery, but about a third of those who
develop postoperative delirium show accelerated cognitive decline out to 36 months following surgery. Our
working definition of complicated delirium, developed in our prior period of support, is delirium associated
with a higher degree (or pace) of cognitive decline in long-term follow-up (i.e., ≥ 2-3 years). In this sub-group,
the pace is similar to that observed among persons with mild cognitive impairment. Defining complicated
delirium in terms of long-term cognitive decline is problematic since the outcome cannot be detected for years.
Therefore, this Project will help identify predictors of complicated delirium to assist with early identification. Our
aims are: (1) to identify predictors for early identification of complicated delirium using an expert panel, (2)
identify predictors for early identification of complicated delirium using empiric data, and (3) to validate the
predictive models in an independent sample (external validity) and against clinical outcomes (predictive
validity). We will use information that is potentially available before, during and immediately following surgery.
We will also evaluate models using biomarkers derived from cerebrospinal fluid, serum, neurophysiologic
measures, and neuroimaging obtained before surgery. We will accomplish our aims with (a) the insights of
experts in delirium in a modified Delphi process; (b) secondary data analysis of the rich data already collected
in the SAGES I cohort, and (c) validation with new observational and clinical data collected within the context
of the new SAGES II cohort study. We will develop multiple models including preoperative, perioperative, and
postoperative predictor variable sets, and their combination. Our team includes experts in qualitative and
quantitative methodology and field leaders in the study of delirium. The ultimate goal of this work is to improve
delirium recognition and treatment by clinicians, and heighten the prognostic importance of delirium among
clinicians, their patients, and policy makers.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard N Jones其他文献
Identifying classes of barriers to performing physical activity
识别进行身体活动的障碍类别
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:1.5
- 作者:
Zachary J. Kunicki;Brittany L. Stevenson;Dominique L. Popescu;Ana M. Abrantes;Richard N Jones;Lisa L. Harlow - 通讯作者:
Lisa L. Harlow
Cognitive performance in functional seizures compared with epilepsy and healthy controls: a systematic review and meta analysis.
与癫痫和健康对照相比,功能性癫痫发作的认知表现:系统评价和荟萃分析。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:64.3
- 作者:
Ryan Van Patten;Tara A Austin;Erica Cotton;Lawrence Chan;John A Bellone;Kristen Mordecai;H. Altalib;Stephen Correia;Elizabeth W Twamley;Richard N Jones;Kelsey Sawyer;W. LaFrance - 通讯作者:
W. LaFrance
Richard N Jones的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard N Jones', 18)}}的其他基金
Psychometric Integrative Technology for Cognitive Health Research
认知健康研究的心理测量综合技术
- 批准号:
8966053 - 财政年份:2015
- 资助金额:
$ 14.88万 - 项目类别:
Psychometric Integrative Technology for Cognitive Health Research
认知健康研究的心理测量综合技术
- 批准号:
9270487 - 财政年份:2015
- 资助金额:
$ 14.88万 - 项目类别:
Psychometric Integrative Technology for Cognitive Health Research
认知健康研究的心理测量综合技术
- 批准号:
9140087 - 财政年份:2015
- 资助金额:
$ 14.88万 - 项目类别:
Understanding Disparities in Mental Status Assessment
了解心理状态评估的差异
- 批准号:
7369785 - 财政年份:2005
- 资助金额:
$ 14.88万 - 项目类别:
Understanding Disparities in Mental Status Assessment
了解心理状态评估的差异
- 批准号:
7173365 - 财政年份:2005
- 资助金额:
$ 14.88万 - 项目类别:
Understanding Disparities in Mental Status Assessment
了解心理状态评估的差异
- 批准号:
6859138 - 财政年份:2005
- 资助金额:
$ 14.88万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 14.88万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 14.88万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 14.88万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 14.88万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 14.88万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 14.88万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 14.88万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 14.88万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 14.88万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 14.88万 - 项目类别: